The week in pharma: action, reaction and insight - week to December 3, 2021
By Barbara Obstoj-Cardwell
M&A featured in last week’s news, with US cancer specialist Blueprint Medicines last Monday revealing it was acquiring Lengo Therapeutics for up to $465 million to bolster its lung cancer drug pipeline. Also, French pharma major Sanofi last Wednesday announced it was buying Austrian biotech firm Origimm to expand its vaccines R&D portfolio along with its acne candidate ORI-001. On the research front, US gene therapy company Krystal Biotech soared last Monday after it released positive clinical trial results for its Vyjuvek (beremagene geperpavec) in the treatment of epidermolysis bullosa. Also, Quell Therapeutics raised $156 million in a Series B financing, with the proceeds to be used to accelerate research on its QEL-001 CAR-T reg cell therapy.
Looking past Big Pharma rivals, Blueprint buys a pre-clinical biotech
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze